Nitrofurantoin (Macrobid) is NOT appropriate for treating Group B Streptococcus UTI
Nitrofurantoin should not be used for this infection because Group B Streptococcus (GBS) is not among the FDA-approved susceptible organisms for Macrobid, which is specifically indicated only for E. coli and Staphylococcus saprophyticus. 1
Why Nitrofurantoin Fails Here
The FDA label for Macrobid explicitly states it is "indicated only for the treatment of acute uncomplicated urinary tract infections (acute cystitis) caused by susceptible strains of Escherichia coli or Staphylococcus saprophyticus" 1. Group B Streptococcus is conspicuously absent from this list.
Furthermore, the FDA label warns that "nitrofurantoins lack the broader tissue distribution of other therapeutic agents approved for urinary tract infections" and that "many patients who are treated with Macrobid are predisposed to persistence or reappearance of bacteriuria" 1. This is particularly concerning with GBS, which can cause serious complications if inadequately treated.
The Colony Count Context
While 80,000 CFU/mL is below the traditional 100,000 CFU/mL threshold for "significant bacteriuria," this distinction matters less with GBS. In pregnancy specifically, any level of GBS bacteriuria (regardless of CFU/mL) warrants intrapartum antibiotic prophylaxis 2. If this patient is pregnant, she requires appropriate intravenous antibiotics during labor, not oral nitrofurantoin now.
For non-pregnant patients with symptomatic UTI and GBS at 80,000 CFU/mL, treatment is still warranted if symptoms are present, but nitrofurantoin remains the wrong choice due to lack of established efficacy.
What to Use Instead
For GBS urinary tract infections, use antibiotics with proven activity against streptococcal species:
- Penicillins (amoxicillin, ampicillin) - first-line for GBS
- Cephalosporins (cephalexin, cefadroxil) - alternative option
- Trimethoprim-sulfamethoxazole - if susceptibility confirmed, though resistance patterns vary 3
The European Association of Urology guidelines recommend cephalosporins as alternatives for uncomplicated cystitis when first-line agents are inappropriate 3, which applies here since the pathogen is not covered by first-line agents.
Critical Pitfall to Avoid
Do not assume that because nitrofurantoin is "first-line for uncomplicated cystitis" 3, 4 it works for all uropathogens. The guidelines and research supporting nitrofurantoin as first-line therapy specifically address E. coli-predominant infections 4, 5, 6. GBS represents a different pathogen requiring different antimicrobial coverage.
Obtain culture and susceptibility testing to guide definitive therapy 1, and select an antibiotic with documented GBS activity while awaiting results.